Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) EBT Margin (2018 - 2025)

Serina Therapeutics' EBT Margin history spans 8 years, with the latest figure at 4287.69% for Q2 2025.

  • For Q2 2025, EBT Margin rose 389466.0% year-over-year to 4287.69%; the TTM value through Sep 2025 reached 20168.97%, down 2003064.0%, while the annual FY2024 figure was 31382.14%, 3126521.0% down from the prior year.
  • EBT Margin for Q2 2025 was 4287.69% at Serina Therapeutics, down from 39757.14% in the prior quarter.
  • Across five years, EBT Margin topped out at 39757.14% in Q4 2024 and bottomed at 63880.0% in Q1 2022.
  • The 5-year median for EBT Margin is 8182.35% (2024), against an average of 15237.33%.
  • The largest annual shift saw EBT Margin plummeted -6032107bps in 2022 before it soared 6038667bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 8377.78% in 2021, then plummeted by -312bps to 34500.0% in 2022, then soared by 101bps to 247.52% in 2023, then soared by 15962bps to 39757.14% in 2024, then crashed by -111bps to 4287.69% in 2025.
  • Per Business Quant, the three most recent readings for SER's EBT Margin are 4287.69% (Q2 2025), 39757.14% (Q4 2024), and 38057.14% (Q3 2024).